Pre-made Spesolimab benchmark antibody ( Whole mAb, anti-IL36RN/IL-36R therapeutic antibody, Anti-FIL1/FIL1(DELTA)/FIL1D/IL1F5/IL1HY1/IL1L1/IL1RP3/IL36RA/PSORP/PSORS14 Antibody) for drug discovery and mechanism of action (MOA) research
Cat No.: GMP-Bios-ab-532
Pre-Made Spesolimab biosimilar, Whole mAb, Anti-IL36RN/IL-36R Antibody: Anti-FIL1/FIL1(DELTA)/FIL1D/IL1F5/IL1HY1/IL1L1/IL1RP3/IL36RA/PSORP/PSORS14 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Spesolimab (BI 655130) is a humanised monoclonal antibody being developed by Boehringer Ingelheim, for the treatment of generalised pustular psoriasis, Crohn's disease, palmoplantar pustulosis, ulcerative colitis and atopic dermatitis.
Delivery impact due to the Coronavirus Outbreak
With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.
|Catalog No.||Package||Price(In USD)||Qty (Quantity)||Sum(In USD)|
|Products Name (INN Index)||Pre-Made Spesolimab biosimilar, Whole mAb, Anti-IL36RN/IL-36R Antibody: Anti-FIL1/FIL1(DELTA)/FIL1D/IL1F5/IL1HY1/IL1L1/IL1RP3/IL36RA/PSORP/PSORS14 therapeutic antibody|
|Highest_Clin_Trial (Jan '20)||Phase-III|
|100% SI Structure||6u6u:HL|
|99% SI Structure||None|
|95-98% SI Structure||None|
|Conditions Active||Ulcerative colitis;Atopic dermatitis;Crohn's disease;Palmoplantar pustulosis;Pustular psoriasis|